All News

Big data

Rheumatoid arthritis and the ‘big bang’ at the ACR!

Janet Pope, MD, MPH, FRCPC

Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?

Read Article
RheumNow Podcast square

Pre-ACR25 (10.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and info reports the day before ACR 2025

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
RheumNow Podcast square

Associations in Rheumatology (10.3.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

Big Fat FDA Pink Slip (9.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
JAK Janus

Equal Safety of JAK Inhibitors and TNF Inhibitors

Jack Cush, MD

JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for the treatment of immune-mediated

Read Article
APLAR on blue background

APLAR 2025: What’s New in RA Management?

Aurelie Najm, MD, PhD

The unveiling of the updated 2025 recommendations for RA treatment, presented by Josef Smolen in the plenary session on the first day of the conference, sparked attention. Although not yet formally published, these updated recommendations represent a refined consensus that simplifies decision-making while reinforcing the importance of treat-to-target principles in RA.

Read Article
RheumNow Podcast square

Sjögren's Graduates (8.22.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article
Future,space,time

Rheums Speak: Future of Rheumatoid Arthritis

Jack Cush, MD

The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.

Read Article
liveVote2.jpg

Rheums Speak: Changing Rheumatology Practices & Choices

Jack Cush, MD

RheumNow surveyed clinicians worldwide on how their rheumatology practice, treatment decisions, and career outlooks have changed over the past 20 years. 242 respondents (68% from the USA) shared their perspectives on the changing landscape of rheumatoid arthritis care, practice patterns, and professional development.

Read Article
#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ramiro et al. No significant differences seen between men and women in response to upadacitinib in AxSpA at week 14 or 52. Differs from data on TNFi/IL17i in this regard. Looks to me like men respond a bit quicker and better though... @RheumNow #ACR25 Abstr#589 https://t.co/2m7mrgcG0z

Links:

Richard Conway RichardPAConway ( View Tweet)
DERM on RheumNow (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor https://t.co/bIK3e8sL45
Dr. John Cush RheumNow ( View Tweet)
Phase 3b/4 head-to-head SELECT-SWITCH study tested Humira vs Rinvoq in 492 RA MTX pts failing a TNFi then Rx w/ ADA vs UPA x12 wks. UPA > ADA w/ DAS28-CRP < 3.2 (43% vs 22%; p<0.001) and also for DAS28-CRP < 2.6 (28% vs 14%). No new safety signals seen.https://t.co/EAJ9GglMjv https://t.co/uHTsdTPpWP

Links:

Dr. John Cush RheumNow ( View Tweet)
Muscle mass & JAKi? 15 active RA pts (+ sarcopenia risk) Rx w/ tofacitinib - signif. improved @1 mo. @6 mos muscle mass signif improved (+242 cm3, +4%, p=0·017) {less w/ NSAIDs); w/ signif creatinine incr (0.06 mg/dl) & decr in serum IL-6, IL-1 & TNF. No change in CK, myoglobin, https://t.co/taY7DisMOS
Dr. John Cush RheumNow ( View Tweet)
Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS
Dr. John Cush RheumNow ( View Tweet)
Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did not significantly reduce joint replacement (OR 0.67; 0.41–1.08), BUT TNFi, Non-TNFi biologics & DMARD users had signif fewer surgeries (OR ~0.65) vs NSAID users https://t.co/vnBnFcPxGw
Dr. John Cush RheumNow ( View Tweet)
JAKne? Study of 2183 IBD pts on JAK inhib, 272 developed acne. Crude prevalence: 16% upadacitinib, 4% tofacitinib, 2% filgotinib (dose-dependent w/ UPA & Tofa). JAKne in pts 30–50 yrs; mild-moderate severity; in 1st 3 mos. Higher risk w/ prior hx acne vulgaris (OR 4.9) https://t.co/G29CvZ6aux
Dr. John Cush RheumNow ( View Tweet)
JAKne? Study of 2183 IBD pts on JAK inhib, 272 developed acne. Crude prevalence: 16% upadacitinib, 4% tofacitinib, 2% filgotinib (dose-dependent w/ UPA & Tofa). JAKne in pts 30–50 yrs; mild-moderate severity; in 1st 3 mos. Higher risk w/ prior hx acne vulgaris (OR 4.9) https://t.co/nz8F2lBwe5
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×